Work

Using CDKN2A loss in the context of wildtype TP53 to predict sensitivity for the MDM2 inhibitor milademetan.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.3136

Authors: Vijaya G Tirunagaru, Feng Xu, Trista Hinz, Lynn Heasley, Richard Bryce, Avanish Vellanki, Nora Ku, Robert Charles Doebele

Institutions: University of Colorado Anschutz, University of Colorado Denver

Language: English

Topic: Cancer-related Molecular Pathways

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286297237

Cites:

Cited by:

Related to: 10